ICANS and mortality after CAR-T therapy for NHL patients can be predicted using physical function measures of falls, balance and strength deficits, and use of an assistive device
- PMID: 40968178
- DOI: 10.1038/s41409-025-02714-y
ICANS and mortality after CAR-T therapy for NHL patients can be predicted using physical function measures of falls, balance and strength deficits, and use of an assistive device
Conflict of interest statement
Competing interests: NMN, TH, MMH, EM, AR and GS: No conflicts of interest to disclose. No company provided funding for this study. MD consultant to BMS and Kite/Gilead. SH research funding from Vitrac Therapeutics and Incyte, clinical trial adjudication to CSL Behring, and consults for Sanofi, Ossium, and MaaT Pharma. BCB research support from CTI BioPharma on the Ad Board for Incyte and has IP licensing for CD83 CAR T: CRISPR Tx 2021-2023. PLM consultant to BlueBird Biotech, BMS, Celegene, Fate Therapeutics, Janssen, Juno, Karyopharm, Magenta Therapeutics, Sanofi, and Takeda. Ethics approval and consent to participate: This observational study was approved by the Roswell Park Institutional Review Board and performed in accordance with the Declaration of Helsinki. A waiver of consent was obtained and approved by the Roswell Park Institutional Review Board.
References
-
- Shouse G, Tran R, Osborn J, Budde LE. Physical therapy assessment of baseline function and endurance predicts short term outcomes in commercial CAR T patients with lymphoma. Blood. 2021;138:570. - DOI
-
- Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625–38. - DOI
Publication types
LinkOut - more resources
Full Text Sources